白血病干细胞负荷提升非不良ELN风险组AML的预后精度
该研究评估初治急性髓系白血病(AML)患者白血病干细胞(LSC)负荷的预后意义。采用二代流式细胞术定量LSC,以中位LSC百分比0.386%分为LSCneg/low和LSChigh组。LSC负荷低与完全缓解率更高、MRD阴性率更高及RFS、EFS、OS改善相关,且在CD34+和CD34- AML中均一致。LSC负荷是独立预测因子,整合ELN风险分层和MRD评估可能改善风险细化。
要点
- LSC在93.5%初治AML患者中可检测到,中位频率0.386%。
- LSCneg/low(≤0.386%)组完全缓解率更高(p=0.05),MRD阴性率更高(p=0.002)。
- 低LSC负荷与RFS、EFS、OS改善相关(均p<0.05),CD34+和CD34- AML中一致。
核心结论
- LSC负荷是AML反应和生存的强独立预测因子,与ELN风险分层和MRD评估整合可能增强风险细化和个体化治疗。
研究设计与样本
- 研究评估初治AML患者LSC负荷的预后意义,采用二代流式细胞术定量LSC,以中位LSC百分比0.386%分为LSCneg/low和LSChigh组。
主要发现
- LSC在93.5%患者中可检测到,中位频率0.386%。
- LSCneg/low(≤0.386%)组完全缓解率更高(p=0.05),MRD阴性率更高(p=0.002)。
- 低LSC负荷与RFS、EFS、OS改善相关(均p<0.05)。
- 在CD34+和CD34- AML中,低LSC%均与更优生存结局相关(p<0.05)。
关键数值与推荐
- LSCneg/low定义为LSC百分比≤0.386%(中位值),LSChigh为高于中位值。
临床怎么用
- LSC定量可与ELN风险分层和MRD评估整合,用于增强风险细化和个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukaemic stem cells (LSCs) are chemo-resistant leukaemia-initiating clones that drive refractoriness and relapse in acute myeloid leukaemia (AML). The study evaluated the prognostic significance of LSC burden in treatment naïve AML patients. LSCs were quantified using Next-generation flow cytometry; patients were stratified into LSCneg/low and LSChigh groups based on the median LSC percentage, and correlated with post-induction morphological remission and measurable residual disease (MRD) status, and long-term outcomes including relapse-free survival (RFS), event-free survival (EFS) and overall survival (OS). LSCs were detectable in 93.5% patients, with a median frequency of 0.386%. Patients with LSCneg/low (≤0.386%) had higher rates of complete remission (CR) (p = 0.05) and MRD negativity (p = 0.002). Lower LSC burden was associated with improved RFS, EFS and OS (all p < 0.05) suggesting the prognostic relevance of LSC quantitation in AML. In both Cluster of Differentiation 34 positve (CD34+) and CD34 negative (CD34-) AML, low LSC% was associated with superior survival outcomes (p < 0.05). LSC burden is a strong, independent predictor of response and survival in AML, and its integration with European LeukemiaNet risk-stratification and MRD assessment may enhance risk refinement and individualized therapy.
引用
- Khan A, Gajendra S, Rai S, et al. Leukaemic stem cell burden enhances prognostic precision in the non-adverse European LeukemiaNet risk group of acute myeloid leukaemia. Br J Haematol. 2026. PMID: 42433166. doi:10.1111/bjh.70679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。